In support of this theory, in a phase II study of docetaxel/epirubicin reporting a high incidence of CNS disease, it was found, retrospectively, that a majority of patients developing CNS disease had tumours overexpressing HER-2 (Crivellari et al, 2001). This evidence concerns the gene ERBB2 and neoplasm.